Opus Genetics (IRD) Non-Current Deffered Revenue (2010 - 2018)
Opus Genetics (IRD) posted quarterly Non-Current Deffered Revenue of $19900.0 for Q4 2018, down 94.69% year-over-year from $375000.0 in Q4 2017, and down 33.33% quarter-over-quarter from $29850.0 in Q3 2018.
Powered by 
Analysis
Opus Genetics (IRD) Non-Current Deffered Revenue (2010 - 2018) Analysis & Trends
Opus Genetics (IRD) has reported Non-Current Deffered Revenue for 9 consecutive years, with $19900.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue fell 94.69% year-over-year to $19900.0; the TTM figure through Dec 2018 stood at $19900.0 (down 94.69% YoY), while the FY2018 annual figure was $19900.0, down 94.69% from the prior year.
- Non-Current Deffered Revenue declined to $19900.0 in Q4 2018 per IRD's latest filing, from $29850.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $782280.0 in Q1 2014 and bottomed at $19900.0 in Q4 2018.
- Historically, Non-Current Deffered Revenue has averaged $244258.7 across 5 years, with a median of $115444.0 in 2015.
- Annual changes were most pronounced in 2014 — Non-Current Deffered Revenue jumped 1408.66% — and 2018, when it sank 94.69%.
- Opus Genetics' Non-Current Deffered Revenue stood at $129710.0 in 2014, then decreased by 19.81% to $104020.0 in 2015, then decreased by 23.86% to $79204.0 in 2016, then soared by 373.46% to $375000.0 in 2017, then tumbled by 94.69% to $19900.0 in 2018.
- Business Quant data shows IRD's Non-Current Deffered Revenue at $19900.0 in Q4 2018, $29850.0 in Q3 2018, and $39575.0 in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 19,900.00 |
| Sep 30, 2018 | 29,850.00 |
| Jun 30, 2018 | 39,575.00 |
| Mar 31, 2018 | 48,150.00 |
| Dec 31, 2017 | 375,000.00 |
| Sep 30, 2017 | 393,750.00 |
| Jun 30, 2017 | 412,500.00 |
| Mar 31, 2017 | 431,250.00 |
| Dec 31, 2016 | 450,000.00 |
| Sep 30, 2016 | 468,750.00 |
| Jun 30, 2016 | 487,500.00 |
| Mar 31, 2016 | 506,250.00 |
| Dec 31, 2015 | 525,000.00 |
| Sep 30, 2015 | 543,750.00 |
| Jun 30, 2015 | 562,500.00 |
| Mar 31, 2015 | 581,250.00 |
| Dec 31, 2014 | 600,000.00 |
| Sep 30, 2014 | 618,750.00 |
| Jun 30, 2014 | 678,156.00 |
| Mar 31, 2014 | 782,280.00 |